Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Intracavernosal Injection Systems

Caverject / Edex (alprostadil) & compounded Trimix / Bimix / Quadmix

Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
FDA Approved (alprostadil: Caverject, Edex); Trimix/Bimix compounded (off-label)

Reference only. Not medical advice.

What can go wrong

The signature risks are priapism and pain. Prolonged/painful erections lasting over 4 hours are a medical emergency requiring aspiration and/or intracavernosal phenylephrine. Reported priapism rates vary widely by agent and dose (alprostadil labeling cites ~0.4% priapism and ~4% prolonged erection; broader estimates of priapism across ICI regimens range far higher, and adding papaverine raises the risk). Penile pain is common with alprostadil (roughly 1-11%), and repeated injection can cause tunical fibrosis (~5-7%). First dose should be titrated in-office by a clinician.

This is something to take to a clinician. The Atlas can tell you what is known about intracavernosal injection systems in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Intracavernosal injection (ICI) therapy delivers a vasoactive drug directly into the corpus cavernosum with a fine needle or auto-injector to produce an erection independent of arousal. FDA-approved single-agent alprostadil (prostaglandin E1) is sold as Caverject and Edex, while pharmacy-compounded combinations, Trimix (alprostadil + papaverine + phentolamine), Bimix, and Quadmix, are widely used off-label and are often cheaper per dose. ICI is among the most effective non-surgical ED treatments, with efficacy reported over 70% and up to ~90% in selected use.

The most reliable non-surgical option, delivered by needle.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Severe or refractory ED
  • ED after radical prostatectomy
  • Diabetic and cardiovascular ED
  • Men who fail oral PDE5 inhibitors
  • Penile rehabilitation programs

How it works

Injected vasoactive agents relax cavernosal smooth muscle and dilate penile arteries, driving inflow and producing an erection that does not require arousal or intact neural signaling. Alprostadil (PGE1) acts via prostaglandin receptors; Trimix adds papaverine (a nonspecific phosphodiesterase inhibitor) and phentolamine (an alpha-blocker) for a synergistic effect at lower alprostadil doses.

What people get wrong

  • Often saidInjections are only a last resort before surgery

    ActuallyICI is a mainstream, highly effective second-line therapy used long before implant surgery is considered; many men use it successfully for years.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Set against the alternatives

ICI is more reliable than pills for severe, diabetic, or post-prostatectomy ED and works when PDE5 inhibitors fail, but it requires self-injection, carries priapism/fibrosis risk, and has high discontinuation over time. Compounded Trimix is often more cost-effective than single-agent alprostadil because lower drug quantities achieve similar results.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Branded alprostadil is expensive at retail (Caverject roughly $1,000 for six doses, Edex around $290 for two, before coupons/copay cards), whereas compounded Trimix from a compounding pharmacy is usually substantially cheaper per erection, which drives its off-label popularity.

At a glance

Route
Direct intracavernosal injection / auto-injector
FDA agents
Alprostadil (Caverject, Edex)
Compounded
Trimix, Bimix, Quadmix (off-label)
Efficacy
~70-90%; patient satisfaction ~87-93%

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Intracavernosal Injection Systems. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Linet & Ogrinc, NEJM alprostadil efficacy/safety1996

    Established efficacy and safety of intracavernosal alprostadil in men with ED

  • Pooled ICI outcomesreported

    Efficacy >70% across general and comorbid ED populations; patient satisfaction ~87-93.5%, partner ~86-90%

  • Priapism/complication reviewsreported

    Priapism 0.25-1% in some series (higher in others); penile pain 1-11%; fibrosis ~5-7%